Bank of America Corp DE Purchases Shares of 2,009,835 The Cooper Companies, Inc. $COO

Key Points

• Bank of America acquired 2,009,835 shares of Cooper Companies in the second quarter, valued at approximately $144.1 million and representing about 1.03% of the company.
• Analysts maintain a consensus “Hold” rating with a $71.47 price target, although several firms recently lowered their targets amid concerns about the company’s outlook.
• Cooper Companies beat quarterly EPS estimates ($1.15 versus $1.12), but revenue missed expectations at $1.07 billion. The company also authorized a $3 billion share-repurchase program, while directors made notable insider purchases.

Bank of America Corp DE purchased a new stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 2,009,835 shares of the medical device company's stock, valued at approximately $144,125,000. Bank of America Corp DE owned about 1.03% of Cooper Companies at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Root Financial Partners LLC increased its holdings in shares of Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company's stock worth $26,000 after buying an additional 162 shares during the last quarter. Essential Partners LLC lifted its stake in Cooper Companies by 23.4% during the first quarter. Essential Partners LLC now owns 874 shares of the medical device company's stock worth $62,000 after purchasing an additional 166 shares during the last quarter. Allworth Financial LP grew its position in Cooper Companies by 14.1% during the fourth quarter. Allworth Financial LP now owns 1,355 shares of the medical device company's stock valued at $111,000 after acquiring an additional 167 shares during the last quarter. SJS Investment Consulting Inc. raised its position in Cooper Companies by 107.5% in the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company's stock worth $26,000 after purchasing an additional 187 shares during the period. Finally, Nicolet Advisory Services LLC increased its holdings in shares of Cooper Companies by 7.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,291 shares of the medical device company's stock worth $274,000 after buying an additional 242 shares during the period. Hedge funds and other institutional investors own 24.39% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on COO shares. Mizuho set a $75.00 price objective on Cooper Companies and gave the stock an "outperform" rating in a report on Thursday, September 10th. KeyCorp reaffirmed a "sector weight" rating on shares of Cooper Companies in a research report on Friday, June 5th. Needham & Company LLC dropped their target price on shares of Cooper Companies from $86.00 to $73.00 and set a "buy" rating for the company in a research report on Thursday, September 10th. JPMorgan Chase & Co. cut their target price on shares of Cooper Companies from $71.00 to $58.00 and set a "neutral" rating on the stock in a research note on Thursday, September 10th. Finally, Citigroup reiterated a "neutral" rating and set a $60.00 price target (down from $80.00) on shares of Cooper Companies in a research report on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $71.47.

Insider Activity at Cooper Companies

In other news, Director Walter M. Rosebrough, Jr. bought 7,000 shares of the firm's stock in a transaction on Friday, September 11th. The stock was acquired at an average cost of $54.11 per share, with a total value of $378,770.00. Following the completion of the acquisition, the director owned 17,000 shares of the company's stock, valued at approximately $919,870. This represents a 70.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence Kurzius bought 10,000 shares of the company's stock in a transaction dated Monday, September 14th. The stock was purchased at an average price of $53.91 per share, for a total transaction of $539,100.00. Following the purchase, the director owned 21,099 shares of the company's stock, valued at approximately $1,137,447.09. This represents a 90.10% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 34,701 shares of company stock valued at $1,880,039 in the last 90 days. Corporate insiders own 2.08% of the company's stock.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $53.78 on Friday. The Cooper Companies, Inc. has a 12 month low of $51.01 and a 12 month high of $89.83. The firm has a market capitalization of $10.23 billion, a P/E ratio of 18.35, a P/E/G ratio of 2.22 and a beta of 0.82. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The business has a fifty day simple moving average of $70.23 and a two-hundred day simple moving average of $68.77.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company had revenue of $1.07 billion during the quarter, compared to analysts' expectations of $1.10 billion. During the same period last year, the company posted $0.49 EPS. Cooper Companies's revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts forecast that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies declared that its Board of Directors has authorized a share repurchase program on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's leadership believes its shares are undervalued.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Director Lawrence Kurzius purchased 10,000 shares for approximately $549,300, increasing his position by 47.4%. Other directors, including Paul Keel and Walter Rosebrough Jr., also recently bought shares. The purchases may provide a modest confidence signal from insiders after the selloff. Insider purchase report
• Neutral Sentiment: Jana Partners is pressing Cooper to replace its chief executive and pursue an urgent overhaul, citing “chronic underperformance.” The activist campaign could create a catalyst for strategic change, but it also increases leadership and execution uncertainty. Wall Street Journal activist report
• Negative Sentiment: Cooper’s latest quarterly results beat adjusted EPS expectations, $1.15 versus $1.12, but revenue of approximately $1.07 billion missed the $1.10 billion consensus. Management also reduced fiscal 2026 adjusted EPS guidance to $4.51–$4.55 and revenue guidance to $4.23–$4.25 billion, reflecting weaker contact-lens demand.
• Negative Sentiment: Reports that U.S. distributors are reducing channel inventories have raised concerns about near-term sales and whether the weakness reflects temporary destocking or softer underlying demand. Inventory destocking report
• Negative Sentiment: Pomerantz, Bragar Eagel & Squire, and Levi & Korsinsky announced investigations into potential securities claims. These notices do not establish wrongdoing, but they add legal and headline risk. Analysts have also lowered their consensus price target to about $72.27. Pomerantz investigation

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.